CareDx (CDNA)

• Market cap: $1.11B
• 1 day: 0.29%
• 5 days: -8.64%
• 1 month: -7.87%
• 3 months: -30.44%
• 6 months: 47.53%
• Year to date: 72.61%
• 1 year: 90.48%
• 5 years: -9.61%
• 10 years: 174.80%
• Sector: Healthcare
• Industry: Medical Laboratories

About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

Employees: 643

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

555% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 11

204% more call options, than puts

Call options by funds: $4.18M | Put options by funds: $1.38M

92% more capital invested

Capital invested by funds: $840M [Q2] → $1.61B (+$770M) [Q3]

67% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]

40% more funds holding

Funds holding: 154 [Q2] → 215 (+61) [Q3]

7% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 59

6.0% less ownership

Funds ownership: 103.92% [Q2] → 97.92% (-6.0%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 70% upside
• Avg. target: $35 70% upside
• High target: $35 70% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BTIG Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target	70% upside $35	Buy Maintained	5 Nov 2024
Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target	70% upside $35	Buy Maintained	16 Oct 2024